What is the primary purpose of the joint research between Alivexis and Astellas Pharma?

The primary purpose of the joint research is to discover new small molecule compounds and create innovative therapeutic drugs for drug discovery targets selected by Astellas.

What is ModBind™ and what is its significance in this collaboration?

ModBind™ is Alivexis's proprietary physics-based simulation technology that accurately predicts binding strength between small molecules and target proteins without experimental data, significantly aiding in drug discovery.

What is the history of joint research between Alivexis and Astellas Pharma?

This is the second joint research agreement, following a previous project initiated in June 2024, where Astellas exercised its option to acquire rights to the research results in September 2025.

What are the respective roles of Alivexis and Astellas Pharma in this joint research?

Alivexis will be responsible for integrated drug discovery research, including experimental systems and compound synthesis/evaluation, while Astellas will select drug discovery targets and acquire option rights to the research results.

What evidence demonstrates the effectiveness of Alivexis's platform technologies like ModBind™?

Alivexis has produced five clinical candidates using its platform technologies, and one, MDI-0151, was out-licensed for approximately 42.5 billion yen, showcasing the platform's utility.

AI News NQ Analysis

Alivexis initiates joint research with Astellas Pharma on novel drug discovery targets.

NQ Score 56/100

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the primary purpose of the joint research between Alivexis and Astellas Pharma?: A: The primary purpose of the joint research is to discover new small molecule compounds and create innovative therapeutic drugs for drug discovery targets selected by Astellas.
Q: What is ModBind™ and what is its significance in this collaboration?: A: ModBind™ is Alivexis's proprietary physics-based simulation technology that accurately predicts binding strength between small molecules and target proteins without experimental data, significantly aiding in drug discovery.
Q: What is the history of joint research between Alivexis and Astellas Pharma?: A: This is the second joint research agreement, following a previous project initiated in June 2024, where Astellas exercised its option to acquire rights to the research results in September 2025.
Q: What are the respective roles of Alivexis and Astellas Pharma in this joint research?: A: Alivexis will be responsible for integrated drug discovery research, including experimental systems and compound synthesis/evaluation, while Astellas will select drug discovery targets and acquire option rights to the research results.
Q: What evidence demonstrates the effectiveness of Alivexis's platform technologies like ModBind™?: A: Alivexis has produced five clinical candidates using its platform technologies, and one, MDI-0151, was out-licensed for approximately 42.5 billion yen, showcasing the platform's utility.